title: [Study of visual acuity and intraocular pressure in the treatment of macular diabetic edema with intravitreous triamcinolone].
abstract: OBJECTIVE
  To evaluate the effect of intravitreal triamcinolone acetonide in patients with diffuse diabetic macular edema on the visual acuity and intraocular pressure. To report the potential adverse events and to analyze the potential relationship between age and visual acuity and intraocular pressure variability.
  
  
  METHODS
  This clinical controlled study included 14 patients (28 eyes), 14 of the eyes received an intravitreal injection of 4 mg triamcinolone acetonide for the treatment of diabetic macular edema. The study group was compared to a control group of 14 eyes, without diabetic macular edema. The follow-up period was of 3 months.
  
  
  RESULTS
  Pressure spikes >21 mmHg occurred in 28.7% of eyes, with a significant difference of intraocular pressure between the study group and the control group in the first week after treatment. Visual acuity showed a significant improvement when compared with the control group since the second day after the treatment. There was no association between age and variability of visual acuity and intraocular pressure.
  
  
  CONCLUSIONS
  Intravitreal triamcinolone acetonide showed to be effective for improving visual acuity in patients with diabetic macular edema, in the first three months of treatment. The incidence of intraocular hypertension was 28.7%, easily manageable.
authors.affiliation: Hospital do Servidor Público Estadual de São Paulo, São Paulo, SP, Brasil. marcussipr@hotmail.com
authors.forename: Marcussi Palata
authors.initials: MP
authors.lastname: Rezende
authors.forename: Alana Ferreira Gomes
authors.initials: AF
authors.lastname: Dias
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Oshima
authors.forename: Eric Pinheiro de
authors.initials: EP
authors.lastname: Andrade
authors.forename: Pedro Durães
authors.initials: PD
authors.lastname: Serracarbassa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016022:Case-Control Studies; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects; D014792:Visual Acuity / Q000187:drug effects*; D014822:Vitreous Body
chemical_list: D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide